Get the Stockscreener App
1.31
0.00%
0.00
Humacyte Inc stock is traded at $1.31, with a volume of 2.13M.
It is up +0.00% in the last 24 hours and up +4.80% over the past month.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
See More
Previous Close:
$1.31
Open:
$1.32
24h Volume:
2.13M
Relative Volume:
0.41
Market Cap:
$245.33M
Revenue:
-
Net Income/Loss:
$-110.78M
P/E Ratio:
-1.2243
EPS:
-1.07
Net Cash Flow:
$-75.59M
1W Performance:
+6.50%
1M Performance:
+4.80%
6M Performance:
-45.64%
1Y Performance:
-67.89%
1-Day Range:
$1.29
$1.34
1-Week Range:
$1.21
$1.34
52-Week Range:
$1.09
$6.77
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
1.31 | 245.33M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-27-25 | Initiated | Barclays | Overweight |
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Is Humacyte Inc a good long term investmentStraddle and Strangle Trades & Explosive Capital Growth Plans - earlytimes.in
Humacyte Stock (HUMA) Opinions on FDA Approval for Symvess Product - Quiver Quantitative
Humacyte (HUMA): Benchmark Remains Bullish on Stock - Finviz
Humacyte (HUMA): Benchmark remains bullish on stock - MSN
Humacyte prices 28.4M shares at $2.11 in registered direct offering - MSN
Market Moves: Can Humacyte Inc stock weather global recessionPortfolio Risk Report & Reliable Intraday Trade Plans - moha.gov.vn
Bond Watch: Will Humacyte Inc Equity Warrant stock pay special dividendsJuly 2025 Volume & Low Volatility Stock Recommendations - BỘ NỘI VỤ
Book value per share of Humacyte, Inc. Warrant 2021-27.08.26 on Humacyte – NASDAQ:HUMAW - TradingView
Wall Street analysts see Humacyte, Inc. (HUMA) as a buy: Should you invest? - MSN
Wall Street Analysts See Humacyte, Inc. (HUMA) as a Buy: Should You Invest? - Finviz
How Humacyte Inc. Equity Warrant stock reacts to global recession fearsBuy Signal & High Accuracy Buy Signal Tips - Newser
Can Humacyte Inc. stock continue upward trendPortfolio Growth Summary & Momentum Based Trading Signals - Newser
Humacyte, Inc. (NASDAQ:HUMA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
11 Best Micro-Cap Stocks to Invest in According to Analysts - Insider Monkey
Humacyte, Inc. (HUMA) Reports Q3 Loss, Misses Revenue Estimates - MSN
Humacyte, Inc.'s (NASDAQ:HUMA) largest shareholders are retail investors with 57% ownership, institutions own 26% - Yahoo Finance
Will Humacyte Inc. stock maintain growth storyForecast Cut & High Accuracy Trade Alerts - Newser
Can Humacyte Inc. stock maintain growth trajectoryMarket Volume Summary & Fast Moving Stock Trade Plans - BỘ NỘI VỤ
Humacyte (HUMA) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Humacyte stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
What drives Humacyte Inc stock priceGap Up/Gap Down Analysis & Collaborate and Win Together - earlytimes.in
Humacyte, Inc. (NASDAQ:HUMA) Q4 2024 Earnings Call Transcript - MSN
Humacyte (HUMA) Q3 2025 Earnings Call Transcript - The Globe and Mail
Humacyte Ends Sale Agreement with Jefferies LLC - TipRanks
HumacyteOn Nov 21, co delivered notice to Jefferies terminating open market sale agreement entered on Sept 1, 2022 - MarketScreener
Aug Closing: What catalysts could drive Humacyte Inc. stock higherJuly 2025 Analyst Calls & Consistent Profit Alerts - BỘ NỘI VỤ
Aug Wrap: Can Humacyte Inc. stock maintain growth trajectory2025 Retail Activity & Growth Oriented Trading Recommendations - moha.gov.vn
Humacyte Stock Continues Slide Despite Lower Than Expected Q4 Loss – But Retail Gets More Bullish - MSN
Humacyte’s Major Breakthroughs Impress Investors: Market Reactions - StocksToTrade
Stock Traders Purchase Large Volume of Humacyte Put Options (NASDAQ:HUMA) - MarketBeat
Humacyte Inc. (HUMA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
D. Boral Capital Maintains Humacyte (HUMA) Buy Recommendation - MSN
D. Boral Capital Reiterates "Buy" Rating for Humacyte (NASDAQ:HUMA) - MarketBeat
Humacyte, Inc. (HUMA) stock price, news, quote and history - Yahoo Finance UK
Quantitative breakdown of Humacyte Inc. recent moveMarket Movers & Long-Term Growth Plans - newser.com
Humacyte releases press info on VEITH symposium presentation - Traders Union
D. Boral Capital Reiterates "Buy" Rating for Humacyte (HUMA) | H - GuruFocus
Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results - The Manila Times
Humacyte (Nasdaq: HUMA) Details ATEV Recellularization and 2-Year Trauma Data - Stock Titan
What recovery options are there for Humacyte Inc. Equity WarrantWeekly Profit Summary & Long-Term Capital Growth Strategies - newser.com
Real time pattern detection on Humacyte Inc. stockPortfolio Gains Report & Step-by-Step Trade Execution Guides - newser.com
Will Humacyte Inc. Equity Warrant stock see insider buyingDividend Hike & Real-Time Stock Movement Alerts - newser.com
Will Humacyte Inc. see short term momentumJuly 2025 Sector Moves & Stepwise Trade Execution Plans - newser.com
Will Humacyte Inc. stock deliver shareholder valueJuly 2025 Summary & Risk Controlled Daily Plans - newser.com
Is Humacyte Inc. stock supported by strong cash flows2025 AllTime Highs & Low Risk Growth Stock Ideas - newser.com
How to interpret RSI for Humacyte Inc. stock2025 Valuation Update & Precise Buy Zone Identification - newser.com
Multi asset correlation models including Humacyte Inc. Equity WarrantWeekly Trade Review & Verified Short-Term Plans - newser.com
Is Humacyte Inc. Equity Warrant stock ready for a breakoutInsider Selling & Real-Time Price Movement Reports - newser.com
Is Humacyte Inc. Equity Warrant stock attractive for retirement portfolios - newser.com
Is Humacyte Inc. Equity Warrant stock attractive for growth ETFsQuarterly Trade Review & Daily Risk Controlled Trade Plans - newser.com
Will Humacyte Inc. stock benefit from infrastructure spendingEarnings Risk Summary & High Accuracy Trade Signal Alerts - newser.com
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):